What Matters Most to Lung Cancer Patients? A Qualitative Study in Italy and Belgium to Investigate Patient Preferences

What Matters Most to Lung Cancer Patients? A Qualitative Study in Italy and Belgium to Investigate Patient Preferences

Background: The potential value of patient preference studies has been recognized in clinical individual treatment decision-making between clinicians and patients, as well as in upstream drug decision-making. Drug developers, regulators, reimbursement and Health Technology Assessment (HTA) bodies ar...

Full description

Bibliographic Details
Main Authors: Serena Petrocchi, Rosanne Janssens, Serena Oliveri, Reinhard Arnou, Ilaria Durosini, Paolo Guiddi, Evelyne Louis, Marie Vandevelde, Kristiaan Nackaerts, Meredith Y. Smith, Giulia Galli, Filippo de Marinis, Letizia Gianoncelli, Gabriella Pravettoni, Isabelle Huys
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Pharmacology
Subjects:
patient preferences
drug decision-making
drug development
patient-centered research
lung cancer
benefit-risk assessment
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.602112/full

Similar Items

Similar Items